As stated in the report of Credit Suisse, the third quarterly revenue of SH PHARMA (02607.HK) +0.080 (+0.414%) Short selling $643.69K; Ratio 4.148%
shot up 27.7% to RMB 24.703 billion. Excluding special items, the
increasing rate of earnings recorded a year-on-year increase of 13.9%,
an acceleration from 5.8% in the first half of the year. It is believed
that the annual core earnings will record a double-digit growth. The
target price of Shanghai Pharmaceuticals was lifted from $15.04 to $19,
which represents 15x of P/E. The rating was maintained at Neutral.
Hopewell Hold (00054) sells Hopewell Infr stake for $9.9B Hopewell Holdings (00054) has agreed to sell 2.055 billion shares of Hopewell Highway Infrastructure (00737) , representing 66.69% of the issued share capital of the company, to Shenzhen Investment International Capital Holdings Infrastructure Co. to HK$9.865 billion in cash, or HK$4.8 per share, which has a discount of 3.61% to the closing price of HK$4.98 per share on 29 December 2017. Upon completion of the deal, the purchaser and parties acting in concert with it will own a total of 66.69% stake in Hopewell Highway Infrastructure and the purchaser will be required to make an unconditional mandatory cash offer for all other issued shares of Hopewell Highway Infrastructure also at HK$4.8 per share. The total consideration of the offer will be HK$4.927 billion assuming full acceptance of the offer. The offeror intends to maintain Hopewell Highway Infrastructure's share listing following the close of...
Comments
Post a Comment